Brought to you by 
Aveo Pharmaceuticals closes IPO and nets $83.4mm
27 Apr 2012
Executive Summary
Cancer therapy developer Aveo Pharmaceuticals completed its initial public offering, netting $83.4mm through the sale of 9.97mm common shares (including the exercise of 969k of the 1.35mm shares marked for the overallotment) at $9 each. The company initially filed in December 2009, and last month announced its intention to sell 7mm shares priced between $13-15.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com